Literature DB >> 16001634

Successful surgical treatment for hepatocellular carcinoma and concomitant risky esophageal varices.

Satoshi Yamamoto1, Yoshinobu Sato, Toshiyuki Takeishi, Kenichiro Hirano, Takashi Kobayashi, Takaoki Watanabe, Katsuyoshi Hatakeyama.   

Abstract

BACKGROUND/AIMS: In our frequent encounters with liver cirrhotic patients with hepatocellular carcinoma (HCC) and concomitant risky esophageal varices, we have found that some of them required endoscopic injection sclerotherapy (EIS) and/or surgical treatment for esophageal variceal bleeding due to increased portal venous pressure after aggressive hepatectomy. In this study, we investigated the short-term effect of aggressive hepatectomy accompanied with left gastric venous caval shunt (Inokuchi's shunt) for esophageal varices and postoperative liver function.
METHODOLOGY: Four cirrhotic patients with HCC and concomitant risky esophageal varices underwent hepatectomy with Inokuchi's shunt from 1999 to 2001. The mean age was 58.0 +/- 15.3 years old and all patients were classified in Child grade A or B. We investigated hematochemical data and endoscopic findings before and after surgery.
RESULTS: One of the patients experienced disappearance of esophageal varices at discharge. In the others, postoperative endoscopy showed disappearance of CRS and reduced sizes of varices. In one patient, hepatic encephalopathy appeared transiently with bleeding from a duodenal ulcer at one month after surgery. However, the patient improved by conservative treatment. Three of the patients have survived well without recurrence of HCC and esophageal variceal bleeding; the remaining patient died from a recurrence of HCC.
CONCLUSIONS: Inokuchi's shunt may be sufficiently effective to treat risky esophageal varices associated with resectable HCC and may be safe even if it is undertaken along with a major hepatectomy.

Entities:  

Mesh:

Year:  2005        PMID: 16001634

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Zinc protoporphyrin IX enhances chemotherapeutic response of hepatoma cells to cisplatin.

Authors:  Yang-Sui Liu; Huan-Song Li; Dun-Feng Qi; Jun Zhang; Xin-Chun Jiang; Kui Shi; Xiao-Jun Zhang; Xin-Hui Zhang
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.

Authors:  Cheng Jin; Haimin Li; Yong He; Min He; Ling Bai; Yunxin Cao; Wenjie Song; Kefeng Dou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

3.  Beneficial effect of partial portal decompression using the inferior mesenteric vein for intractable gastroesophageal variceal bleeding in patients with liver cirrhosis.

Authors:  Satoshi Yamamoto; Yoshinobu Sato; Hideki Nakatsuka; Hiroshi Oya; Takashi Kobayashi; Katsuyoshi Hatakeyama
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.